Why were these PTC Therapeutics (PTCT) CEO share sales executed?

The footnotes state that the sales represent shares automatically sold pursuant to irrevocable sell-to-cover elections made upon acceptance of RSU grants to satisfy tax withholding obligations in connection with RSU vesting on grants dated January 3, 2025 and January 5, 2023.

PTC CEO Klein sells shares to cover RSU taxes

Q: What insider transaction did PTC Therapeutics (PTCT) report for Matthew B. Klein?

PTC Therapeutics reported that Chief Executive Officer and Director Matthew B. Klein sold shares of common stock in two transactions on January 6, 2026 and January 7, 2026, both reported on a Form 4 as sales of directly owned shares.

Q: How many PTC Therapeutics (PTCT) shares did the CEO sell and at what prices?

On January 6, 2026, 5,149 shares of PTC Therapeutics common stock were sold at $76.95 per share. On January 7, 2026, an additional 3,016 shares were sold at $77.48 per share.

Q: What RSU grants are linked to the PTC Therapeutics (PTCT) CEO’s sell-to-cover transactions?

The sell-to-cover sales relate to the vesting of 17,500 RSUs from a January 3, 2025 grant of 70,000 RSUs and 6,500 RSUs from a January 5, 2023 grant of 26,000 RSUs.

Q: Is the PTC Therapeutics (PTCT) CEO considered a 10% owner in this filing?

No. In this Form 4, Matthew B. Klein is identified as a Director and Chief Executive Officer, and the 10% owner box is not checked.

PTC Therapeutics, Inc. (PTCT) CEO Matthew B. Klein reported automatic sales of common stock tied to RSU vesting.

Filing Impact

(Very High)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

PTC Therapeutics, Inc. (PTCT) CEO Matthew B. Klein reported automatic sales of common stock tied to RSU vesting. On January 6, 2026, 5,149 shares of common stock were sold at $76.95 per share, and on January 7, 2026, 3,016 shares were sold at $77.48 per share. Both transactions are coded as sales and are reported as directly owned shares.

According to the footnotes, these sales were made under irrevocable "sell to cover" elections to satisfy tax withholding obligations arising from the vesting of 17,500 RSUs from a January 3, 2025 grant of 70,000 RSUs and 6,500 RSUs from a January 5, 2023 grant of 26,000 RSUs. After these transactions, Klein directly beneficially owns 396,967 shares of PTC Therapeutics common stock.

Insider Trade Summary

Net Seller: 8,165 shares

Net Sell 2 txns

Insider Klein Matthew B.

Role CHIEF EXECUTIVE OFFICER

Sold 8,165 shs ($630K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,016	$77.48	$234K
Sale	Common Stock	5,149	$76.95	$396K

Holdings After Transaction: Common Stock — 396,967 shares (Direct)

Footnotes (2)

F1. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 17,500 RSUs from a January 3, 2025 grant of 70,000 RSUs.
F2. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 6,500 RSUs from a January 5, 2023 grant of 26,000 RSUs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PTC Therapeutics (PTCT) report for Matthew B. Klein?

PTC Therapeutics reported that Chief Executive Officer and Director Matthew B. Klein sold shares of common stock in two transactions on January 6, 2026 and January 7, 2026, both reported on a Form 4 as sales of directly owned shares.

How many PTC Therapeutics (PTCT) shares did the CEO sell and at what prices?

On January 6, 2026, 5,149 shares of PTC Therapeutics common stock were sold at $76.95 per share. On January 7, 2026, an additional 3,016 shares were sold at $77.48 per share.

How many PTC Therapeutics (PTCT) shares does CEO Matthew B. Klein own after these transactions?

Following the reported transactions, CEO Matthew B. Klein is shown as beneficially owning 396,967 shares of PTC Therapeutics common stock directly.

What RSU grants are linked to the PTC Therapeutics (PTCT) CEO’s sell-to-cover transactions?

The sell-to-cover sales relate to the vesting of 17,500 RSUs from a January 3, 2025 grant of 70,000 RSUs and 6,500 RSUs from a January 5, 2023 grant of 26,000 RSUs.

Is the PTC Therapeutics (PTCT) CEO considered a 10% owner in this filing?

No. In this Form 4, Matthew B. Klein is identified as a Director and Chief Executive Officer, and the 10% owner box is not checked.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 01/08/2026 - 05:20 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Klein Matthew B.

(Last)

(First)

(Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN

07059

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF EXECUTIVE OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/06/2026		S		5,149⁽¹⁾	D	$76.95	399,983	D
Common Stock	01/07/2026		S		3,016⁽²⁾	D	$77.48	396,967	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 17,500 RSUs from a January 3, 2025 grant of 70,000 RSUs.

2. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 6,500 RSUs from a January 5, 2023 grant of 26,000 RSUs.

	/s/ Avraham S. Adler, Attorney-in-Fact	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR